One To Watch

Definium Therapeutics

A late-stage CNS biotechnology company, formerly MindMed, advancing lysergide-based therapeutics for major depressive disorder and generalized anxiety disorder after landmark Phase III data in 2026.

Company Overview

A late-stage CNS biotechnology company, formerly MindMed, advancing lysergide-based therapeutics for major depressive disorder and generalized anxiety disorder after landmark Phase III data in 2026. Definium Therapeutics (Nasdaq: DFTX) is making the case that a rigorously formulated, single-dose LSD-derived compound can clear the regulatory bar that has eluded psychedelic-adjacent medicine for decades. With three Phase III readouts expected in 2026, the company is now one of the closest things to a near-term commercial psychedelic drug sponsor in public markets. The positive Emerge data, announced June 22, 2026, validated that thesis — at least for MDD — and triggered a capital raise to match the ambition.

Headquarters and Global Presence

Definium Therapeutics is headquartered in New York, NY, and trades on Nasdaq under the ticker DFTX. The company's operational footprint reflects its clinical-stage status, with activities centered on trial execution across its CNS pipeline.

Founding and History

The company was founded as Mind Medicine (MindMed), one of the earliest publicly traded psychedelic drug developers, before rebranding to Definium Therapeutics in early 2026 to signal a pivot toward conventional late-stage pharmaceutical development. The rebrand accompanied a strategic sharpening of focus on its late-stage CNS pipeline, with DT120 as the lead asset. The name change also reflected an intent to distance the company from the broader, more speculative psychedelic-wellness space and position it as a serious regulatory-pathway company. Three Phase III readouts expected in 2026 mark the most consequential period in the company's history.

Therapy Areas and Focus

Definium is focused exclusively on central nervous system disorders spanning psychiatry and neurology, with MDD and generalized anxiety disorder as the primary near-term indications. MDD affects hundreds of millions globally, and a meaningful proportion of patients fail to respond adequately to existing antidepressants — precisely the unmet need Definium is targeting. The company's bet is that a single, precisely dosed psychedelic-derived molecule, administered under controlled conditions, can deliver durable antidepressant effects where chronic daily dosing regimens have fallen short. The GAD indication broadens the addressable population and gives DT120 a potential second regulatory pathway if MDD approval proceeds.

Technology Platforms and Modalities

Definium's platform is built around lysergide — a compound in the LSD chemical class — formulated as an orally disintegrating tablet designed for precise, reproducible dosing. The ODT format is clinically meaningful: it removes the variability of oral liquid formulations and supports the kind of standardized delivery that regulators and trial designers require. DT120 is administered as a single 100 microgram dose, a regimen designed to capture acute neuroplasticity effects while minimizing the prolonged perceptual disruption associated with higher recreational doses. The company's approach — controlled dose, controlled setting, placebo-controlled trial design — represents a deliberate effort to meet the FDA on conventional pharmaceutical terms rather than seeking an alternative pathway.

Key Pipeline and Programs

DT120 is Definium's lead asset: an orally disintegrating tablet of lysergide (LSD-derived), targeting serotonin receptor pathways, in Phase III development for both MDD and GAD. In MDD, the Phase III Emerge study — a randomized, double-blind, placebo-controlled trial evaluating a single 100 microgram dose — reported positive topline results on June 22, 2026. DT120 produced a least squares mean MADRS score reduction of 13.3 points from baseline versus 5.2 points for placebo at Week 6, a placebo-adjusted improvement of 8.1 points (p less than 0.0001). A secondary endpoint at Week 12 showed a 7.3-point placebo-adjusted improvement, also statistically significant — suggesting the antidepressant effect extends well beyond the acute dosing window. DT120 was well tolerated with no serious adverse events and no suicidality signal, addressing a key regulatory concern for any CNS asset in this space. The GAD program represents a second Phase III opportunity within the 2026 readout calendar, and the company has flagged a third Phase III readout also expected this year, positioning DT120 as potentially the most clinically validated psychedelic-derived compound in development.

Recent Developments

On June 22, 2026, Definium announced that the Phase III Emerge study of DT120 in MDD met its primary endpoint and all key secondary endpoints, representing the first positive randomized controlled Phase III data for a single-dose lysergide compound in a major psychiatric indication. The same day, the company announced a proposed public offering of $500 million in common shares and pre-funded warrants, with underwriters holding an option to purchase up to an additional $75 million — a financing scale that reflects commercial-readiness ambitions. Analyst response was swift: Oppenheimer raised its price target to $60 from $40 (Outperform), and Leerink raised its target to $52 from $30, with Needham also upgrading its target. The rebrand from MindMed to Definium Therapeutics was completed in early 2026, preceding the Emerge readout.

Key Personnel

The research context does not name specific executives at Definium Therapeutics. The company's leadership team is guiding a late-stage pipeline through what is, by any measure, a pivotal regulatory year for the organization.

Strategic Partnerships

No specific partnership or licensing agreements are disclosed in the available research context. The $500 million equity offering announced alongside the Emerge data suggests Definium is pursuing an independent commercialization path rather than an out-licensing strategy — at least for the near term. The scale of the capital raise implies the company intends to self-fund regulatory submissions and, potentially, commercial infrastructure if DT120 advances to approval.

FAQ Section

The rebrand from MindMed to Definium Therapeutics, completed in early 2026, was a deliberate repositioning away from the speculative psychedelic-wellness space toward a conventional late-stage pharmaceutical identity. Trading on Nasdaq as DFTX, the company is signaling that it intends to pursue standard FDA regulatory pathways with placebo-controlled Phase III data — the Emerge study being the proof point. The timing, ahead of multiple Phase III readouts in 2026, was clearly strategic: arrive at the data with a name that reads like a serious drug developer.

Lysergide acts on serotonin receptor pathways and is understood to promote neuroplasticity — the brain's capacity to form new connections — in ways that conventional daily antidepressants do not replicate. The hypothesis is that a single acute dose can reset pathological patterns of rumination and mood dysregulation in a way that then sustains beyond the pharmacological window. Definium's Emerge data appear to support this: the antidepressant effect at Week 12 remained statistically significant after a single 100 microgram dose, which is the clinically and commercially interesting result.

DT120 is formulated as an orally disintegrating tablet — a standardized pharmaceutical format that ensures reproducible dosing and is straightforward to administer in a clinical setting. The 100 microgram dose is calibrated to produce therapeutic neurobiological effects while avoiding the prolonged perceptual disruption associated with higher doses, a design choice that matters both clinically and regulatorily. Running the Emerge study as a randomized, double-blind, placebo-controlled trial — the gold standard — also distinguishes DT120 from programs that have relied on open-label or observer-blinded designs.

Emerge was the first randomized, double-blind, placebo-controlled Phase III trial of a single-dose lysergide compound in MDD. DT120 produced a placebo-adjusted MADRS score improvement of 8.1 points at Week 6 (p less than 0.0001), with a 7.3-point improvement at Week 12 also reaching statistical significance — indicating durability beyond the acute dosing period. No serious adverse events and no suicidality signal were recorded, addressing two of the FDA's highest-sensitivity concerns for psychiatric drug candidates. The study met both its primary endpoint and all key secondary endpoints, giving Definium a clean dataset to take into regulatory discussions.

Definium's pipeline spans psychiatry and neurology, with DT120 also in late-stage development for generalized anxiety disorder — a large and underserved indication where current pharmacotherapy (primarily SSRIs and SNRIs) leaves many patients with residual symptoms. The company has indicated three Phase III readouts expected in 2026, suggesting at least one additional indication or program beyond MDD and GAD is generating near-term data. The CNS focus is deliberate and concentrated, rather than diversified across unrelated disease areas.

Definium is at the most consequential inflection point of its history: Phase III data from Emerge in MDD are now in hand, and at least two further Phase III readouts are expected within 2026. A positive MDD dataset positions the company to engage with the FDA on a New Drug Application, while the pending GAD and additional readouts will determine the breadth of DT120's regulatory opportunity. The $500 million equity offering announced alongside the Emerge data suggests the company is actively building the capital base needed for regulatory filing and potential commercialization.

The Emerge MDD data are genuinely positive, but several watchpoints remain before Definium can be considered a commercial-stage company:

Remaining Phase III readouts for GAD and any additional indication in 2026 — replication across indications is critical to the investment and regulatory thesis.
FDA engagement: how the agency frames the regulatory pathway for a single-dose psychedelic-derived compound is uncharted territory, and labeling, REMS requirements, or scheduling considerations could all complicate commercialization.
The $500 million equity raise will dilute existing shareholders and tests the market's conviction in the DT120 platform at current valuations.
Commercial infrastructure: without disclosed partnership agreements, Definium appears to be planning independent commercialization, which is capital-intensive and operationally untested for the organization.
The DEA scheduling status of lysergide could create access and distribution constraints even after FDA approval, a regulatory variable outside Definium's direct control.

Want to Update your Company's Profile?